271 related articles for article (PubMed ID: 20388847)
1. Crosstalk between insulin/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer.
Rozengurt E; Sinnett-Smith J; Kisfalvi K
Clin Cancer Res; 2010 May; 16(9):2505-11. PubMed ID: 20388847
[TBL] [Abstract][Full Text] [Related]
2. Metformin prevents tobacco carcinogen--induced lung tumorigenesis.
Memmott RM; Mercado JR; Maier CR; Kawabata S; Fox SD; Dennis PA
Cancer Prev Res (Phila); 2010 Sep; 3(9):1066-76. PubMed ID: 20810672
[TBL] [Abstract][Full Text] [Related]
3. The role of an anti-diabetic drug metformin in the treatment of endocrine tumors.
Thakur S; Daley B; Klubo-Gwiezdzinska J
J Mol Endocrinol; 2019 Aug; 63(2):R17-R35. PubMed ID: 31307011
[TBL] [Abstract][Full Text] [Related]
4. STAT3/LKB1 controls metastatic prostate cancer by regulating mTORC1/CREB pathway.
Pencik J; Philippe C; Schlederer M; Atas E; Pecoraro M; Grund-Gröschke S; Li WJ; Tracz A; Heidegger I; Lagger S; Trachtová K; Oberhuber M; Heitzer E; Aksoy O; Neubauer HA; Wingelhofer B; Orlova A; Witzeneder N; Dillinger T; Redl E; Greiner G; D'Andrea D; Östman JR; Tangermann S; Hermanova I; Schäfer G; Sternberg F; Pohl EE; Sternberg C; Varady A; Horvath J; Stoiber D; Malcolm TI; Turner SD; Parkes EE; Hantusch B; Egger G; Rose-John S; Poli V; Jain S; Armstrong CWD; Hoermann G; Goffin V; Aberger F; Moriggl R; Carracedo A; McKinney C; Kennedy RD; Klocker H; Speicher MR; Tang DG; Moazzami AA; Heery DM; Hacker M; Kenner L
Mol Cancer; 2023 Aug; 22(1):133. PubMed ID: 37573301
[TBL] [Abstract][Full Text] [Related]
5. Metformin for aging and cancer prevention.
Anisimov VN
Aging (Albany NY); 2010 Nov; 2(11):760-74. PubMed ID: 21084729
[TBL] [Abstract][Full Text] [Related]
6. The complexities of obesity and diabetes with the development and progression of pancreatic cancer.
Bao B; Wang Z; Li Y; Kong D; Ali S; Banerjee S; Ahmad A; Sarkar FH
Biochim Biophys Acta; 2011 Apr; 1815(2):135-46. PubMed ID: 21129444
[TBL] [Abstract][Full Text] [Related]
7. The Intricate Crosstalk Between Insulin and Pancreatic Ductal Adenocarcinoma: A Review From Clinical to Molecular.
Deng J; Guo Y; Du J; Gu J; Kong L; Tao B; Li J; Fu D
Front Cell Dev Biol; 2022; 10():844028. PubMed ID: 35252207
[TBL] [Abstract][Full Text] [Related]
8. The Synergistic Effect of an ATP-Competitive Inhibitor of mTOR and Metformin on Pancreatic Tumor Growth.
Soliman GA; Shukla SK; Etekpo A; Gunda V; Steenson SM; Gautam N; Alnouti Y; Singh PK
Curr Dev Nutr; 2020 Sep; 4(9):nzaa131. PubMed ID: 32908958
[TBL] [Abstract][Full Text] [Related]
9. The insulin-like growth factor system and its receptors: A potential novel anticancer target.
Lindsay CR; Evans TJ
Biologics; 2008 Dec; 2(4):855-64. PubMed ID: 19707463
[TBL] [Abstract][Full Text] [Related]
10. Dietary and pharmacological modification of the insulin/IGF-1 system: exploiting the full repertoire against cancer.
Klement RJ; Fink MK
Oncogenesis; 2016 Feb; 5(2):e193. PubMed ID: 26878387
[TBL] [Abstract][Full Text] [Related]
11. Corrigendum to "Scattered DUSP28 is a novel biomarker responsible for aggravating malignancy via the autocrine and paracrine signaling in metastatic pancreatic cancer" [Cancer Lett. 456 (2019 Aug 1) 1-12].
Lee J; Lee J; Kim JH
Cancer Lett; 2024 Feb; 583():216454. PubMed ID: 38044256
[No Abstract] [Full Text] [Related]
12. Diabetes, pancreatic cancer, and metformin therapy.
Gong J; Robbins LA; Lugea A; Waldron RT; Jeon CY; Pandol SJ
Front Physiol; 2014; 5():426. PubMed ID: 25426078
[TBL] [Abstract][Full Text] [Related]
13. Repurposing of metformin and aspirin by targeting AMPK-mTOR and inflammation for pancreatic cancer prevention and treatment.
Yue W; Yang CS; DiPaola RS; Tan XL
Cancer Prev Res (Phila); 2014 Apr; 7(4):388-97. PubMed ID: 24520038
[TBL] [Abstract][Full Text] [Related]
14. Different patterns of Akt and ERK feedback activation in response to rapamycin, active-site mTOR inhibitors and metformin in pancreatic cancer cells.
Soares HP; Ni Y; Kisfalvi K; Sinnett-Smith J; Rozengurt E
PLoS One; 2013; 8(2):e57289. PubMed ID: 23437362
[TBL] [Abstract][Full Text] [Related]
15. Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types.
Iliopoulos D; Hirsch HA; Struhl K
Cancer Res; 2011 May; 71(9):3196-201. PubMed ID: 21415163
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of ageing: growth hormone, dietary restriction, and metformin.
Khan J; Pernicova I; Nisar K; Korbonits M
Lancet Diabetes Endocrinol; 2023 Apr; 11(4):261-281. PubMed ID: 36848915
[TBL] [Abstract][Full Text] [Related]
17. Weight-centric prevention of cancer.
Anazco D; Acosta A; Cathcart-Rake EJ; D'Andre SD; Hurtado MD
Obes Pillars; 2024 Jun; 10():100106. PubMed ID: 38495815
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic Strategies for Pancreatic-Cancer-Related Type 2 Diabetes Centered around Natural Products.
Park MN
Int J Mol Sci; 2023 Nov; 24(21):. PubMed ID: 37958889
[TBL] [Abstract][Full Text] [Related]
19. IGF-1R targeting in cancer - does sub-cellular localization matter?
Soni UK; Jenny L; Hegde RS
J Exp Clin Cancer Res; 2023 Oct; 42(1):273. PubMed ID: 37858153
[TBL] [Abstract][Full Text] [Related]
20. Drugging IGF-1R in cancer: New insights and emerging opportunities.
Wang P; Mak VC; Cheung LW
Genes Dis; 2023 Jan; 10(1):199-211. PubMed ID: 37013053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
